For ErbB signaling, Ohno etal. [166] demonstrated in 2013 that engineered, systemically injected Exos were able to target specifically EGFR‐expressing breast cancer cells thereby effectively delivering microRNAs. This evidence concerns the gene EGFR and breast carcinoma.